Supplementary Table S2 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

2026 Open access

Read full text
Authors: Bruna Pellini, Russell William Madison, Merrida A. Childress, Shoshana T. Miller, Ole V. Gjoerup, Jason Cheng, Richard S.P. Huang, Michael R. Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich
+6 more Marcus Ballinger, MC Liu, Amanda G. Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski
DOI: 10.1158/1078-0432.31084990
Cited by: 0

Abstract

ctDNA decrease from C1 to C4 was associated with greater objective response in patients treated with chemoIO at all cutoffs. Number of patients per best objective response with associated increase or decreases in ctDNA between C1 and C4. *Progression-free rate was calculated from the start of therapy rather than the start of C4D1.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Publication date
19 January 2026